Answers are grounded in this paper and cite their sources.
A higher percentage of participants who received ubrogepant than of those who received placebo had freedom from pain and absence of the most bothersome symptom at 2 hours after the dose. The most commonly reported adverse events were nausea, somnolence, and dry mouth. Further trials are needed to determine the durability and safety of ubrogepant for acute migraine treatment and to compare it with other drugs for migraine. (Funded by Allergan; ClinicalTrials.gov number, NCT02828020.).
No takes yet. Share an insight, caveat, or question.
Dodick et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: